Investigation of DNA Methylation for Identifying Fetal Alcohol Spectrum Disorder

Introduction to Fetal Alcohol Spectrum Disorder

Fetal alcohol spectrum disorder (FASD) is a prevalent and preventable cause of developmental disabilities in children. This spectrum encompasses various presentations, including physical abnormalities, stunted growth, cognitive and behavioral deficits, as well as impairments in motor, sensory, and immune systems. At the most severe end is fetal alcohol syndrome (FAS), characterized by slow growth, distinctive facial malformations, and central nervous system complications.

Challenges in Diagnosis

While many children with fetal alcohol syndrome are diagnosed early due to visible facial deformities, those with less severe forms of FASD may go undetected. These children often lack the obvious physical characteristics associated with FAS, yet they can still experience significant cognitive and behavioral challenges. Early diagnosis is crucial, as it is a strong predictor of positive developmental outcomes. Unfortunately, the current reliance on maternal self-reporting of prenatal alcohol use is often inaccurate, leading to an underestimation of alcohol consumption during pregnancy.

The Need for Improved Screening Tools

Historically, there have been limited screening tools available to identify children at risk for fetal alcohol spectrum disorder. A recent Canadian study published in *Clinical Epigenetics* offers a promising new approach to early identification.

Epigenetic Insights into Fetal Alcohol Exposure

Understanding DNA Methylation

Researchers investigated DNA changes to detect early alcohol exposure, focusing on epigenetics—modifications that alter gene function without changing the DNA sequence. Specifically, DNA methylation, which involves adding a methyl group to parts of a DNA sequence, serves as a valuable biomarker for environmental exposure and disease.

Study Overview and Findings

The study analyzed DNA methylation patterns in 48 individuals aged 3.5 to 18 years, comprising 24 with fetal alcohol spectrum disorder and 24 without. Researchers utilized a specialized test to assess 485,512 methylation sites across the human genome. They identified a specific DNA methylation pattern linked to fetal alcohol spectrum disorder.

Implications for Future Diagnosis

These findings represent a significant advancement towards the use of epigenetic biomarkers in diagnosing fetal alcohol spectrum disorder. The potential to adapt this method for diagnosing other developmental disorders is also noteworthy. An early and accurate diagnosis could greatly enhance the success rates of available treatments, making these results particularly valuable for healthcare providers.

Reference

Lussier AA, Morin AM, Maclsaac JL, Salmon J, Weinberg J, Reynolds JN, Pavlidis P, Chudley AE, Kobor MS. DNA methylation as a predictor of fetal alcohol spectrum disorder. Clinical Epigenetics; 2018, 10:5. DOI 10.1186/s13148-018-0439-6.